Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: Nonlinearities in clearance and bioavailability

Radojka M. Savic, Yanhui Lu, Erin Bliven-Sizemore, Marc Weiner, Eric Nuermberger, William Burman, Susan E. Dorman, Kelly Elise Dooley

Research output: Contribution to journalArticle

Abstract

Rifapentine is under active investigation as a potent drug that may help shorten the tuberculosis (TB) treatment duration. A previous rifapentine dose escalation study with daily dosing indicated a possible decrease in bioavailability as the dose increased and an increase in clearance over time for rifapentine and its active metabolite, desacetyl rifapentine. This study aimed to assess the effects of increasing doses on rifapentine absorption and bioavailability and to evaluate the clearance changes over 14 days. A population analysis was performed with nonlinear mixed-effects modeling. Absorption, time-varying clearance, bioavailability, and empirical and semimechanistic autoinduction models were investigated. A one-compartment model linked to a transit compartment absorption model best described the data. The bioavailability of rifapentine decreased linearly by 2.5% for each 100-mg increase in dose. The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters.h-1, respectively, after a single dose to 2.2 and 5.0 liters.h-1, respectively, after 14 once-daily doses, with no plateau being reached by day 14. In clinical trial simulations using the final model, rifapentine demonstrated less-than-dose-proportional pharmacokinetics, but there was no plateau in exposures over the dose range tested (450 to 1,800 mg), and divided dosing increased exposures significantly. Thus, the proposed compartmental model incorporating daily dosing of rifapentine over a wide range of doses and time-related changes in bioavailability and clearance provides a useful tool for estimation of drug exposure that can be used to optimize rifapentine dosing for TB treatment. (This study has been registered at ClinicalTrials.gov under registration no. NCT01162486.)

Original languageEnglish (US)
Pages (from-to)3035-3042
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
StatePublished - 2014

Fingerprint

rifapentine
Biological Availability
Healthy Volunteers
Pharmacokinetics
Population
Tuberculosis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers : Nonlinearities in clearance and bioavailability. / Savic, Radojka M.; Lu, Yanhui; Bliven-Sizemore, Erin; Weiner, Marc; Nuermberger, Eric; Burman, William; Dorman, Susan E.; Dooley, Kelly Elise.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 6, 2014, p. 3035-3042.

Research output: Contribution to journalArticle

Savic, Radojka M. ; Lu, Yanhui ; Bliven-Sizemore, Erin ; Weiner, Marc ; Nuermberger, Eric ; Burman, William ; Dorman, Susan E. ; Dooley, Kelly Elise. / Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers : Nonlinearities in clearance and bioavailability. In: Antimicrobial Agents and Chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3035-3042.
@article{7da1f546cb18434b8baa4ac22cd221ae,
title = "Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: Nonlinearities in clearance and bioavailability",
abstract = "Rifapentine is under active investigation as a potent drug that may help shorten the tuberculosis (TB) treatment duration. A previous rifapentine dose escalation study with daily dosing indicated a possible decrease in bioavailability as the dose increased and an increase in clearance over time for rifapentine and its active metabolite, desacetyl rifapentine. This study aimed to assess the effects of increasing doses on rifapentine absorption and bioavailability and to evaluate the clearance changes over 14 days. A population analysis was performed with nonlinear mixed-effects modeling. Absorption, time-varying clearance, bioavailability, and empirical and semimechanistic autoinduction models were investigated. A one-compartment model linked to a transit compartment absorption model best described the data. The bioavailability of rifapentine decreased linearly by 2.5{\%} for each 100-mg increase in dose. The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters.h-1, respectively, after a single dose to 2.2 and 5.0 liters.h-1, respectively, after 14 once-daily doses, with no plateau being reached by day 14. In clinical trial simulations using the final model, rifapentine demonstrated less-than-dose-proportional pharmacokinetics, but there was no plateau in exposures over the dose range tested (450 to 1,800 mg), and divided dosing increased exposures significantly. Thus, the proposed compartmental model incorporating daily dosing of rifapentine over a wide range of doses and time-related changes in bioavailability and clearance provides a useful tool for estimation of drug exposure that can be used to optimize rifapentine dosing for TB treatment. (This study has been registered at ClinicalTrials.gov under registration no. NCT01162486.)",
author = "Savic, {Radojka M.} and Yanhui Lu and Erin Bliven-Sizemore and Marc Weiner and Eric Nuermberger and William Burman and Dorman, {Susan E.} and Dooley, {Kelly Elise}",
year = "2014",
doi = "10.1128/AAC.01918-13",
language = "English (US)",
volume = "58",
pages = "3035--3042",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers

T2 - Nonlinearities in clearance and bioavailability

AU - Savic, Radojka M.

AU - Lu, Yanhui

AU - Bliven-Sizemore, Erin

AU - Weiner, Marc

AU - Nuermberger, Eric

AU - Burman, William

AU - Dorman, Susan E.

AU - Dooley, Kelly Elise

PY - 2014

Y1 - 2014

N2 - Rifapentine is under active investigation as a potent drug that may help shorten the tuberculosis (TB) treatment duration. A previous rifapentine dose escalation study with daily dosing indicated a possible decrease in bioavailability as the dose increased and an increase in clearance over time for rifapentine and its active metabolite, desacetyl rifapentine. This study aimed to assess the effects of increasing doses on rifapentine absorption and bioavailability and to evaluate the clearance changes over 14 days. A population analysis was performed with nonlinear mixed-effects modeling. Absorption, time-varying clearance, bioavailability, and empirical and semimechanistic autoinduction models were investigated. A one-compartment model linked to a transit compartment absorption model best described the data. The bioavailability of rifapentine decreased linearly by 2.5% for each 100-mg increase in dose. The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters.h-1, respectively, after a single dose to 2.2 and 5.0 liters.h-1, respectively, after 14 once-daily doses, with no plateau being reached by day 14. In clinical trial simulations using the final model, rifapentine demonstrated less-than-dose-proportional pharmacokinetics, but there was no plateau in exposures over the dose range tested (450 to 1,800 mg), and divided dosing increased exposures significantly. Thus, the proposed compartmental model incorporating daily dosing of rifapentine over a wide range of doses and time-related changes in bioavailability and clearance provides a useful tool for estimation of drug exposure that can be used to optimize rifapentine dosing for TB treatment. (This study has been registered at ClinicalTrials.gov under registration no. NCT01162486.)

AB - Rifapentine is under active investigation as a potent drug that may help shorten the tuberculosis (TB) treatment duration. A previous rifapentine dose escalation study with daily dosing indicated a possible decrease in bioavailability as the dose increased and an increase in clearance over time for rifapentine and its active metabolite, desacetyl rifapentine. This study aimed to assess the effects of increasing doses on rifapentine absorption and bioavailability and to evaluate the clearance changes over 14 days. A population analysis was performed with nonlinear mixed-effects modeling. Absorption, time-varying clearance, bioavailability, and empirical and semimechanistic autoinduction models were investigated. A one-compartment model linked to a transit compartment absorption model best described the data. The bioavailability of rifapentine decreased linearly by 2.5% for each 100-mg increase in dose. The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters.h-1, respectively, after a single dose to 2.2 and 5.0 liters.h-1, respectively, after 14 once-daily doses, with no plateau being reached by day 14. In clinical trial simulations using the final model, rifapentine demonstrated less-than-dose-proportional pharmacokinetics, but there was no plateau in exposures over the dose range tested (450 to 1,800 mg), and divided dosing increased exposures significantly. Thus, the proposed compartmental model incorporating daily dosing of rifapentine over a wide range of doses and time-related changes in bioavailability and clearance provides a useful tool for estimation of drug exposure that can be used to optimize rifapentine dosing for TB treatment. (This study has been registered at ClinicalTrials.gov under registration no. NCT01162486.)

UR - http://www.scopus.com/inward/record.url?scp=84901283254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901283254&partnerID=8YFLogxK

U2 - 10.1128/AAC.01918-13

DO - 10.1128/AAC.01918-13

M3 - Article

C2 - 24614383

AN - SCOPUS:84901283254

VL - 58

SP - 3035

EP - 3042

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -